Galixir, founded in 2019, leverages cutting-edge artificial intelligence technology to enhance drug research and development. By utilizing advanced algorithms and integrating the expertise of computational chemistry, medicinal chemistry, and biology, the company effectively addresses challenges encountered in the early development of small molecule drugs. Galixir expedites the discovery of candidate molecules exhibiting high activity, favorable druggability, and innovative structures. The company collaborates with domestic and international pharmaceutical firms and research institutions to advance a variety of drug research and development pipelines, targeting diverse disease areas including central nervous system diseases, autoimmune diseases, tumors, and respiratory diseases, employing various mechanisms of action such as inhibitors and agonists. Galixir significantly decreases the cost and time involved in preclinical drug development, facilitating the concurrent development of multiple drug pipelines and optimizing overall strategic planning.

Xingyao Technology (星药科技)

Xingyao Technology (星药科技)